Product nameAnti-Ikaros antibody - N-terminal
See all Ikaros primary antibodies
DescriptionRabbit polyclonal to Ikaros - N-terminal
Tested applicationsSuitable for: WB, IP, ChIPmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse
Recombinant fragment within Human Ikaros (N terminal). The exact sequence is proprietary.
Database link: Q13422
- WB: Jurkat, Raji and NCI-H929 whole cell lysate/extract. IP: Raji whole cell extract. ChIP: Jurkat chromatin extract.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.025% Proclin
Constituents: PBS, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab229275 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/3000. Predicted molecular weight: 57 kDa.|
|IP||1/100 - 1/500.|
|ChIP||Use at an assay dependent concentration.|
FunctionTranscription regulator of hematopoietic cell differentiation (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265, PubMed:19141594). Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2 chromatin-remodeling complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex), to the beta-globin locus in adult erythrocytes. Increases normal apoptosis in adult erythroid cells. Confers early temporal competence to retinal progenitor cells (RPCs) (By similarity). Function is isoform-specific and is modulated by dominant-negative inactive isoforms (PubMed:17135265, PubMed:17934067).
Tissue specificityAbundantly expressed in thymus, spleen and peripheral blood Leukocytes and lymph nodes. Lower expression in bone marrow and small intestine.
Involvement in diseaseDefects in IKZF1 are frequent occurrences (28.6%) in acute lymphoblasic leukemia (ALL). Such alterations or deletions lead to poor prognosis for ALL.
Chromosomal aberrations involving IKZF1 are a cause of B-cell non-Hodgkin lymphomas (B-cell NHL). Translocation t(3;7)(q27;p12), with BCL6.
Sequence similaritiesBelongs to the Ikaros C2H2-type zinc-finger protein family.
Contains 6 C2H2-type zinc fingers.
DomainThe N-terminal zinc-fingers 2 and 3 are required for DNA binding as well as for targeting IKFZ1 to pericentromeric heterochromatin.
The C-terminal zinc-finger domain is required for dimerization.
modificationsPhosphorylation controls cell-cycle progression from late G(1) stage to S stage. Hyperphosphorylated during G2/M phase. Dephosphorylated state during late G(1) phase. Phosphorylation on Thr-140 is required for DNA and pericentromeric location during mitosis. CK2 is the main kinase, in vitro. GSK3 and CDK may also contribute to phosphorylation of the C-terminal serine and threonine residues. Phosphorylation on these C-terminal residues reduces the DNA-binding ability. Phosphorylation/dephosphorylation events on Ser-13 and Ser-295 regulate TDT expression during thymocyte differentiation. Dephosphorylation by protein phosphatase 1 regulates stability and pericentromeric heterochromatin location. Phosphorylated in both lymphoid and non-lymphoid tissues (By similarity). Phosphorylation at Ser-361 and Ser-364 downstream of SYK induces nuclear translocation.
Sumoylated. Simulataneous sumoylation on the 2 sites results in a loss of both HDAC-dependent and HDAC-independent repression. Has no effect on pericentromeric heterochromatin location. Desumoylated by SENP1.
Cellular localizationCytoplasm; Nucleus. In resting lymphocytes, distributed diffusely throughout the nucleus. Localizes to pericentromeric heterochromatin in proliferating cells. This localization requires DNA binding which is regulated by phosphorylation / dephosphorylation events and Nucleus. In resting lymphocytes, distributed diffusely throughout the nucleus. Localizes to pericentromeric heterochromatin in proliferating cells. This localization requires DNA binding which is regulated by phosphorylation / dephosphorylation events (By similarity).
- Information by UniProt
FormThere are 7 isoforms produced by alternative splicing.
- CLL associated antigen KW 6 antibody
- DNA-binding protein Ikaros antibody
- hIk 1 antibody
All lanes : Anti-Ikaros antibody - N-terminal (ab229275) at 1/500 dilution
Lane 1 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate/extract
Lane 2 : Raji (human Burkitt's lymphoma cell line) whole cell lysate/extract
Lane 3 : NCI-H929 whole cell lysate/extract
Lysates/proteins at 50 µg per lane.
All lanes : HRP-conjugated anti-rabbit IgG
Developed using the ECL technique.
Predicted band size: 57 kDa
Cross-linked ChIP was performed with Jurkat (Human T cell leukemia cell line from peripheral blood) chromatin extract and 5 μg of either control rabbit IgG or ab229275. The precipitated DNA was detected by PCR with primer set targeting to VPAC-1 receptor promoter.
Ikaros was immunoprecipitated from Raji (human Burkitt's lymphoma cell line) whole cell extract with 4 μg ab229275. Western blot was performed from the immunoprecipitate using ab229275 at 1/500 dilution.
Lane 1: Control IgG IP in Raji whole cell extract.
Lane 2: ab229275 IP in Raji whole cell extract.
ab229275 has not yet been referenced specifically in any publications.